Table 3

Rituximab-mediated sensitization of NHL cell lines to paclitaxel-induced apoptosis

Paclitaxel (nm)
Control0.1110
Raji3.0 ± 2.86.5 ± 1.117.7 ± 2.119.8 ± 1.6
Raji + rituximab4.8 ± 1.212.2 ± 1.3a28.8 ± 1.6b31.2 ± 1.5b
Daudi2.4 ± 1.13.8 ± 2.16.3 ± 0.711.6 ± 1.4
Daudi + rituximab5.9 ± 3.213.3 ± 1.9b18.7 ± 1.6c23.5 ± 1.7b
  • Note: Raji and Daudi cells were treated under the conditions explained in Table 1 and the percentage of apoptosis was determined by flow cytometry. Samples were set up in duplicates and the data are represented as means ± SD (n = 2).

  • a Not significant compared with paclitaxel treatment alone.

  • b P < 0.01 (significant).

  • c P < 0.001 (very significant).